Biomarkers: Accelerating Diagnoses and Guiding Treatments

Register now

  1. Biomarkers: Accelerating Diagnoses and Guiding Treatments

Biomarkers: Accelerating Diagnoses and Guiding Treatments

Join our webinar on April 14th, where we will be discussing a multiomic approach, which combines information from genomics proteomics, and metabolomics, to accelerate the interpretation of data and the development of life-changing biomarkers for rare diseases.

Prof. Peter Bauer, MD, will be hosting the webinar “Biomarkers: Accelerating Diagnoses and Guiding Treatments.” Throughout the webinar, he will provide an overview of the challenges of diagnosing rare diseases and give insights into applying a multiomic approach, including case examples.

Questions and discussion are more than welcome throughout the webinar.

Key topics:

  • Challenges Of Rare Disease Diagnostics
  • Clinical Metabolomics
  • A Multiomic Approach in Practice
  • Case Examples

    Date & Time:

    • Tuesday, April 14, 2020
    • @15:00 CET
    • See when the event will take place in your time zone.

    Unable to attend the webinar? By registering, you will receive a recording of the webinar even if you are unable to attend. If you encounter any problems, please contact us at webinars(at)centogene(dot)com.

    Our speaker

    Dr. Peter Bauer, Chief Genomic Officer

    Prof. Peter Bauer, MD, serves as CENTOGENE’s Chief Genomic Officer, where he combines clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific development, based on his extraordinary experience, especially in high-throughput genetic testing using next-generation sequencing.

    Prof. Bauer received his board certification in Human Genetics in 2006 and headed the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Additionally, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 140 publications in neurogenetics, oncogenetics, cardiogenetics, and sequencing technology.